Compute & Infrastructure
Builds the wafer-fabrication equipment (etch and deposition) chipmakers use to manufacture advanced semiconductors.
{'verdict': '1 signal sits in the elevated band: the AI-monetization gap. This does not trip the convergence flag. Ranks 39th of 68 on composite fragility (F\xa038.75), below Disney and ServiceNow.', 'as_of': '2026-07-11', 'source': 'engine-restatement (T1)', 'snapshot': {'composite_f': 38.75, 'n_elevated': 1, 'convergence': 'watch', 'rank': 39, 'elevated': ['the AI-monetization gap']}}
China was 42% of FY2024 revenue, hit 43% again in Q1 FY2026 before the export rules tightened, and CFO Bettinger quantified a ~$600M CY2026 revenue headwind from the 50% affiliate rule. China guided below 30% of CY2026 revenues. FY2025 China revenue was $6.21B at 34%. How does Lam absorb that headwind while the WFE guidance keeps rising to $140B?
The China figures are confirmed primary: 26% FY2023, 42% FY2024, 34% FY2025 ($6.21B absolute), 43% Q1 FY2026, 35% Q2 FY2026, 34% Q3 FY2026 — all from the FY2025 10-K geographic table and quarterly press releases. The $600M CY2026 headwind from the 50% affiliate rule is from CFO prepared remarks on the Q1 FY2026 call (med-high conf). The WFE $140B CY2026 guide (raised from $135B in January, per Mar Q26 slides) runs in parallel with the China normalization. CEO Archer on the Q3 FY2026 call said spending moved up from $135B since January. The reconciliation the sheet offers: multinationals growing faster than domestic China customers offset the headwind. The Q3 FY2026 call also said June quarter China will decline further — so the offset needs to materialize as China is still falling.
The CFO said on the Q3 FY2026 call that customer down payments are at the lowest level seen in nearly four years — down ~$300M within the deferred balance in the March quarter. If your fastest-growing customers are not pre-committing, what does that say about forward demand conviction?
The down-payment detail is from CFO Bettinger on the Q3 FY2026 earnings call (med-high conf). Deferred revenue declined from a $2.77B peak in Sep 2025 to $2.25B Dec 2025 to $2.22B Mar 2026 — confirmed from quarterly press releases (primary). Combined forward-revenue proxy (deferred $2.22B + Japan acceptance $434M) is ~$2.65B, approximately 0.46× annualized revenue run-rate — thinner than ASML's ~1.2× backlog/revenue ratio. The sheet calls the down-payment low "the most independent fragility signal in this sheet — worth monitoring even while revenue records continue." The Q4 FY2026 guide of $6.60B ±$400M (primary) and WFE $140B are the counter-signals from the same time period.
Forward P/E is ~47× against a semiconductor median of ~37×, and the trailing P/E is ~70×. The stock doubled between the CEO's December 2025 10b5-1 sale at $163.86 and a director's June 2026 10b5-1 sale at ~$350–357. Is that premium justified when China is a confirmed $600M headwind and down payments are at a four-year low?
The P/E figures are from Yahoo Finance and GuruFocus (~46.95–46.69 forward, ~70× trailing, med conf). Semiconductor median ~37× is GuruFocus peer table (med conf). The insider sales are primary: CEO Archer Dec 17, 2025 sold 163,300 shares at $163.86 (~$26.76M, 10b5-1 adopted Aug 19, 2025); Director Brandt Jun 15, 2026 sold 54,500 shares at ~$350–357 (~$19.1M, 10b5-1) — EDGAR primary. The stock doubled in six months between the two plan executions. Both are pre-set 10b5-1 plans — the sheet holds Indicator 3 at AMBER (not red) because neither sale is discretionary and CEO Archer retains 986,105 shares. The sheet's honest conclusion: LRCX is "watch — not alarm," with the down-payment low and China cliff as the two independent fragility signals even as revenue records continue.